GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PTC Therapeutics Inc (NAS:PTCT) » Definitions » Quick Ratio

PTCT (PTC Therapeutics) Quick Ratio : 2.04 (As of Sep. 2024)


View and export this data going back to 2013. Start your Free Trial

What is PTC Therapeutics Quick Ratio?

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. PTC Therapeutics's quick ratio for the quarter that ended in Sep. 2024 was 2.04.

PTC Therapeutics has a quick ratio of 2.04. It generally indicates good short-term financial strength.

The historical rank and industry rank for PTC Therapeutics's Quick Ratio or its related term are showing as below:

PTCT' s Quick Ratio Range Over the Past 10 Years
Min: 1.03   Med: 3.13   Max: 12.12
Current: 2.04

During the past 13 years, PTC Therapeutics's highest Quick Ratio was 12.12. The lowest was 1.03. And the median was 3.13.

PTCT's Quick Ratio is ranked worse than
64.47% of 1503 companies
in the Biotechnology industry
Industry Median: 3.41 vs PTCT: 2.04

PTC Therapeutics Quick Ratio Historical Data

The historical data trend for PTC Therapeutics's Quick Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PTC Therapeutics Quick Ratio Chart

PTC Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Quick Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.22 4.37 1.84 1.65 1.97

PTC Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Quick Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.03 1.97 1.98 2.17 2.04

Competitive Comparison of PTC Therapeutics's Quick Ratio

For the Biotechnology subindustry, PTC Therapeutics's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PTC Therapeutics's Quick Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PTC Therapeutics's Quick Ratio distribution charts can be found below:

* The bar in red indicates where PTC Therapeutics's Quick Ratio falls into.



PTC Therapeutics Quick Ratio Calculation

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.

PTC Therapeutics's Quick Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Quick Ratio (A: Dec. 2023 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(1218.629-30.577)/603.1
=1.97

PTC Therapeutics's Quick Ratio for the quarter that ended in Sep. 2024 is calculated as

Quick Ratio (Q: Sep. 2024 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(1281.55-35.671)/610.712
=2.04

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


PTC Therapeutics  (NAS:PTCT) Quick Ratio Explanation

The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.

In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.

The higher the quick ratio, the better the company's liquidity position.


PTC Therapeutics Quick Ratio Related Terms

Thank you for viewing the detailed overview of PTC Therapeutics's Quick Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


PTC Therapeutics Business Description

Traded in Other Exchanges
Address
100 Corporate Court, South Plainfield, NJ, USA, 07080
PTC Therapeutics Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of orally administered, small-molecule therapeutics. Its target area is RNA biology post-transcriptional control processes of the events occurring in a cell when an RNA messenger is copied from DNA during the transcription process. The discovered products address multiple therapeutic areas, including rare disorders, such as nonsense mutations in Duchenne muscular dystrophy and oncology.
Executives
Mark Elliott Boulding officer: Exec. VP and CLO C/O PTC THERAPEUTICS, INC., 100 CORPORATE COURT, SOUTH PLAINFIELD NJ 07080
Jerome B Zeldis director 8767 E. VIA DE VENTURA, SUITE 190, SCOTTSDALE AZ 85258
Neil Gregory Almstead officer: EVP Research Pharma Ops & Tech C/O PTC THERAPEUTICS, INC., 100 CORPORATE COURT, SOUTH PLAINFIELD NJ 07080
Christine Marie Utter officer: Principal Financial Officer C/O PTC THERAPEUTICS, INC., 100 CORPORATE COURT, SOUTH PLAINFIELD NJ 07080
Pierre Gravier officer: CHIEF FINANCIAL OFFICER C/O PTC THERAPEUTICS, INC., 100 CORPORATE COURT, SOUTH PLAINFIELD NJ 07080
Lee Scott Golden officer: Chief Medical Officer 17199 N. LAUREL PARK DRIVE, SUITE 401, LIVONIA MI 48152
Matthew B. Klein officer: Chief Development Officer C/O PTC THERAPEUTICS, INC., 100 CORPORATE COURT, SOUTH PLAINFIELD NJ 07080
Eric Pauwels officer: Chief Business Officer 550 HILLS DRIVE, BEDMINSTER NJ 07921
Allan Steven Jacobson director PTC THERAPEUTICS, INC., 100 CORPORATE COURT, SOUTH PLAINFIELD NJ 07080
Michael Schmertzler director 110 WASHINGTON STREET, SUITE 1300, CONSHOHOCKEN PA 19428
Alethia Young director C/O GRAPHITE BIO, INC., 201 HASKINS WAY, SUITE 210, SOUTH SAN FRANCISCO CA 94080
Bell William F. Jr. director C/O PTC THERAPEUTICS, INC., 100 CORPORATE COURT, SOUTH PLAINFIELD NJ 07080
Emma Reeve director C/O PAREXEL INTERNATIONAL CORPORATION, 195 WEST STREET, WALTHAM MA 02451
David P Southwell director C/O INOTEK PHARMACEUTICALS CORPORATION, 91 HARTWELL AVENUE, LEXINGTON MA 02421
Emily Luisa Hill officer: Chief Financial Officer C/O PTC THERAPEUTICS, INC., 100 CORPORATE COURT, SOUTH PLAINFIELD NJ 07080